comparemela.com

Latest Breaking News On - Esperion therapeutics inc - Page 1 : comparemela.com

Analyzing Esperion Therapeutics (NASDAQ:ESPR) and Clearmind Medicine (NASDAQ:CMND)

Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) and Clearmind Medicine (NASDAQ:CMND – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, profitability, valuation, dividends and risk. Profitability This table compares Esperion Therapeutics and […]

Canada
Vancouver
British-columbia
Michigan
United-states
Ann-arbor
Daiichi-sankyo-europe-gmb
Cyntar-ventures-inc
Daiichi-sankyo-co
Otsuka-pharmaceutical-co-ltd
Esperion-therapeutics-inc

Clearmind Medicine (NASDAQ:CMND) vs. Esperion Therapeutics (NASDAQ:ESPR) Head-To-Head Analysis

Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) and Clearmind Medicine (NASDAQ:CMND – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings. Analyst Ratings This is a summary of […]

Vancouver
British-columbia
Canada
Ann-arbor
Michigan
United-states
Daiichi-sankyo-europe-gmb
Scisparc-ltd
Clearmind-medicine-inc
Cyntar-ventures-inc
Esperion-therapeutics-inc

Esperion Therapeutics (NASDAQ:ESPR) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a report issued on Tuesday, Benzinga reports. They currently have a $16.00 target price on the biopharmaceutical company’s stock. A number of other equities analysts also recently commented on the company. StockNews.com downgraded Esperion Therapeutics from a strong-buy rating […]

Needham-company
Simplicity-wealth
Esperion-therapeutics-inc
Portfolio-partners
Herbst-group
Esperion-therapeutics
Free-report
Moderate-buy
Get-free-report
Esperion-therapeutics-daily

Esperion Therapeutics (NASDAQ:ESPR) Earns Buy Rating from HC Wainwright

Esperion Therapeutics (NASDAQ:ESPR) Earns Buy Rating from HC Wainwright
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Simplicity-wealth
Portfolio-partners
Herbst-group
Needham-company
Esperion-therapeutics-inc
Esperion-therapeutics
Free-report
Moderate-buy
Get-free-report
Esperion-therapeutics-daily

Analysts Set Esperion Therapeutics, Inc. (NASDAQ:ESPR) Target Price at $9.33

Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) has been assigned a consensus rating of “Hold” from the five research firms that are currently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year target price […]

Monaco
Vanguard-group-inc
Esperion-therapeutics-inc
Bellevue-group
Needham-company
Nasdaq
Armistice-capital
Esperion-therapeutics
Get-free-report
Monaco-asset-management
Asset-management

vimarsana © 2020. All Rights Reserved.